Patent Application
20070112367
1. Field of the Invention
The present invention relates, in general, to medical devices and, in particular, to caps for dermal tissue lancing devices and associated methods.
2. Description of the Related Art
Conventional dermal tissue lancing devices generally have a rigid housing and a lancet that can be armed and launched so as to briefly protrude from one end of the lancing device. For example, conventional lancing devices can include a lancet that is mounted within a rigid housing such that the lancet is movable relative to the rigid housing along a longitudinal axis thereof. Typically, the lancet is spring loaded and launched, upon release of the spring, to penetrate (i.e., “lance”) a target site (e.g., a dermal tissue target site on a user's fingertip). A biological fluid sample (e.g., a whole blood sample) can then be expressed from the penetrated target site for collection and analysis. Conventional lancing devices are described in U.S. Pat. No. 5,730,753 to Morita, U.S. Pat. No. 6,045,567 to Taylor et al. and U.S. Pat. No. 6,071,250 to Douglas et al., each of which is incorporated fully herein by reference.
Dermal tissue lancing devices often include a cap that engages the target site. Such a cap typically has an aperture (i.e., opening), through which the lancet protrudes, and a distal end of the cap will be placed in contact with the target site during use.
When a cap is contacted with a target site, pressure is usually applied to the target site prior to launch of the lancet. This pressure urges the cap against the target site and creates a target site bulge within the opening of the cap. The lancet is then launched to penetrate the target site bulge. A fluid sample, typically blood, is then expressed from the lanced target site for testing. For example, a blood sample expressed from a lanced dermal tissue target site may be tested for the analyte glucose.
A better understanding of the features and advantages of the present invention will be obtained by reference to the following detailed description that sets forth illustrative embodiments, in which the principles of the invention are utilized, and the accompanying drawings in which like numerals indicate like elements, objects and forces, of which:
Referring to
Proximal end 114 is configured for engagement with the dermal tissue lancing device. For example, proximal end 114 can be removeably attached to an end of a suitably modified conventional lancing device by slideably mounting, snap-fitting or screw-fitting proximal end 114 to the end of the dermal tissue lancing device. One skilled in the art can readily modify suitable conventional dermal tissue lancing devices for engagement with a proximal end of caps according to embodiments of the present invention. Suitable conventional dermal tissue lancing devices are described in, for example, U.S. Pat. Nos. 5,730,753, 6,045,567 and 6,071,250, each of which is hereby incorporated in full by reference.
However, once apprised of the present invention, one skilled in the art will appreciate that caps according to embodiments of the present invention are not limited to use with the dermal tissue lancing devices described in the aforementioned patents. Rather, caps according to embodiments of the present invention can be used with any suitable dermal tissue lancing device including, for example, those that employ lancets, hollow needles, solid needles, micro-needles, ultrasonic devices, thermal techniques, and any other suitable technique for extraction of a bodily fluid sample from a dermal tissue target site. In addition, the dermal tissue lancing device can, if desired, include an integrated analytical system for the determination of an analyte (e.g., glucose) in an expressed bodily fluid sample.
Each of the segments of ring-shaped segmented cap body 104 (i.e., cap body segments 122 noted below), includes a distal compression surface 120, borders opening 112 and is revolvingly engaged with a cap body engagement feature 118 and securely engaged with lip 119. Ring-shaped segmented cap body 104 includes a plurality of cap body segments 122 (namely eight cap body segments 122), an outer recess 124, and an inner recess 126. In addition, ring-shaped segmented cap body 104 includes a plurality of dermal tissue engagement features 127 (also referred to as “ridges” 127) on distal compression surface 120. Although, for the purpose of explanation only, eight cap body segments are depicted in the ring-shaped segmented cap body of
Ridges 127 serve to enhance purchase between cap body distal compression surface 120 and a dermal tissue target site. Such enhanced purchase can also be achieved, for example, by forming ring-shaped segmented cap body 104 of a material that is suitably tacky and/or a material that has a suitable high coefficient of friction. An example of such a material is a silica-filled silicone elastomer. Furthermore, enhanced purchase can be achieved via a roughened distal compression surface or a distal compression surface with recesses.
Ring-shaped segmented cap body 104 can be formed of any suitable material including, but not limited to, rigid materials, elastomeric materials, polymeric materials, polyurethane materials, latex materials, silicone materials and combinations thereof. It should be noted that the segmented nature of ring-shaped segmented cap body 104 provides for each cap body segment 122 to revolve about cap body engagement features 118 independently of any other cap body segment and regardless of whether the cap body segments are formed of a rigid or deformable material.
As is explained in further detail herein, when a force is exerted on distal compression surface 120 by the urging of cap 100 against a dermal tissue target site, at least a portion of the ring-shaped segmented cap body 104 revolves while ring-shaped segmented cap body 104 remains securely engaged within outer retainer portion 110 by lip 119. This revolution is evident from a comparison of the relative locations of ring-shaped segmented body 104 in
Cap body segments 122 essentially rest on cap body engagement features 118 and can revolve thereon. Ring-shaped segmented cap body 104 has a generally C-shaped cross-section (see
Opening 112 can have any suitable cross-sectional shape(s) in a direction perpendicular to longitudinal axis A-A including, but not limited to, circular, square, hexagonal, octagonal and triangular cross-sectional shapes. In addition, the cross-section shape can be such that access to opening 112 by, for example, a test strip is provided. Such test strip access enables beneficial in-situ transfer of a blood sample to the test strip as described in U.S. patent application Ser. No. 10/143,399 (published as U.S. 2003/0143113 A2 on Jul. 31, 2003 and hereby incorporated in full by reference), International Application No. PCT/US01/07169 (published as WO 01/64105 A1 on Sep. 7, 2001) and International Application No. PCT/GB02/03772 (published as WO 03/015627 A2 on Feb. 27, 2003).
Referring to
During this inward revolution/rotation, ridges 127 and distal compression surface 120 further engage the dermal tissue target site and form a target site bulge B within opening 112 (see
To increase bodily fluid expression, the applied force can be maintained for a predetermined time period (i.e., a post-lance pressure time period) after lancing (e.g., a post-lance pressure time period in the range of about 2 seconds to about 12 seconds). The amount of expressed bodily fluid can also be increased by also applying and maintaining force prior to lancing (i.e., pre-lance pressure) for a predetermined time period, for example, in the range of 1 seconds to 8 seconds and typically in the range between about 3 seconds and 5 seconds.
Referring to
Ring-shaped deformable cap body 204, including a distal compression surface 220, borders opening 212 and is revolvingly engaged with retainer 202. Ring-shaped deformable cap body 204 includes further a plurality of slits 222, an outer recess 224, and an inner recess 226. In addition, ring-shaped deformable cap body 204 includes a plurality of dermal tissue engagement features 227 (also referred to as “ridges” 227) on distal compression surface 220.
As is explained in further detail herein, when a force is exerted on distal compression surface 220 by the urging of cap 200 against a dermal tissue target site, at least a portion of the ring-shaped deformable cap body 204 revolves while ring-shaped deformable cap body 204 remains securely engaged within retainer 202. The revolution occurs essentially about the circular axis of ring-shaped deformable body 204. Such revolution can be likened to a rotational flexing of the ring-shaped deformable cap body.
Referring to
During this inward revolution/rotation, ridges 227 and distal compression surface 220 further engage the dermal tissue target site and form a target site bulge B within opening 212 (see
During use, there is a potential for dermal tissue lancing device caps to come into contact with blood or other bodily fluid. Such contact could conceivably lead to contamination of the cap with micro-organisms (e.g., bacteria or fungi) or viruses of undesirable activity. However, caps according to embodiments of the present invention can be optionally formed, at least partially, of a suitable anti-microbial material, anti-fungal material and/or anti-viral material that serves to alleviate the undesirable activity of such micro-organisms or viruses. Such a suitable material can be, for example, an anti-microbial plastic, anti-microbial resin and/or anti-microbial silicone. Suitable anti-microbial materials can include, for example, anti-microbial compounds with a trichloro-phenol group, such as 2,4,4-trichloro-2-hydroxy diphenol ether. The anti-microbial compound can be, for example, a coating of the cap or incorporated directly in the cap.
Based on the description of caps 100 and 200 above, one skilled in the art will recognize that caps according to embodiments of the present invention generally include a retainer and a ring-shaped cap body (such as, a ring-shaped deformable cap body or a ring-shaped segmented cap body). Moreover, the retainer has a proximal end configured for engagement with the dermal tissue lancing device, a distal end with a cap body engagement feature (such as a lip) and an opening. In addition, the ring-shaped cap body has a distal compression surface, borders the opening and is securely and revolvingly engaged with the cap body engagement feature. Also, when a force is exerted on the distal compression surface during use of the cap, the ring-shaped cap body revolves (e.g., inward with respect to the opening) while remaining securely engaged with the retainer.
Process 300 includes for contacting a distal compression surface 120 of a ring-shaped segmented cap body 104 of a dermal tissue lancing device cap 100 with the dermal tissue target site TS (see step 310 of
The dermal tissue lancing device cap 100 is then urged towards the dermal tissue target site TS, such that a force is exerted on the distal compression surface 120 that results in the ring-shaped segmented cap body 104 revolving while remaining securely engaged within a retainer (i.e., retainer inner and outer portions 108 and 110, respectively) of the dermal tissue lancing device cap 100. See step 320 of
Subsequently, a target site bulge B of the dermal tissue target site TS is lanced with lancet L of the dermal tissue lancing device, as set forth in step 330 of
A comparative study between a cap for a dermal tissue lancing device according to an embodiment of the present invention (i.e., cap 200 of
The method of testing comprised pressing the cap body (fitted onto the distal end of a conventional lancing device) against a dermal tissue target site of a subject's finger for 3 seconds, lancing the dermal tissue target site with a 28-gauge needle, continuing to hold the cap against the dermal tissue target site for 10 seconds, removing the cap from the dermal tissue target site and collecting blood from the lanced dermal tissue target site with a calibrated glass capillary pipette.
During the lancing step, the subjects rated the amount of discomfort experienced using a subjective scale ranging from 0 to 10. In this subjective scale, a rating of 0 indicated that the subject did not feel any pain during lancing and a rating of 10 indicating that lancing was very painful to the subject. The average subjective score for cap 500 was 2.5 versus 4.3 for the rigid cap. This score indicates that the level of discomfort associated with use of cap 200 is relatively low.
Success was defined as obtaining at least 0.7 microliters of blood (i.e., typically the minimum volume required to give an accurate assessment of an analyte, such as glucose, in blood with hand-held devices). Percent success rate is given for all cap designs tested in Table I below (where n is the number of subjects tested).
The data in Table I indicate a significant percent success rate with cap 200 when compared to the rigid cap. Since the dermal tissue target sites were not physically manipulated (other than by the caps themselves as described above) to enhance blood expression, the success rate indicates that caps according to embodiments of the present invention do not require physical manipulation for blood expression.
It should be understood that various alternatives to the embodiments of the invention described herein may be employed in practicing the invention. It is intended that the following claims define the scope of the invention and that methods and structures within the scope of these claims and their equivalents be covered thereby.
